Soufflé Therapeutics

Soufflé discovers and develops cell-specific ligands to deliver siRNA-based medicines that are rationally designed and transferred across the cell membrane to their target.

Investors

Andrew Hedin

Founded

2022

Partnered

2024

Roadmaps